Finished products that include KSM-66 at a 300-mg dose can use the claims for stress and anxiety, athletic support, and healthy testosterone production.
Ashwagandha products using the KSM-66 ashwagandha brand can now boast a number of functional health claims in the Canadian market. In January, Health Canada issued KSM-66 ashwagandha a Natural Product Number (NPN) and approval three claims, for stress and anxiety, athletic support, and healthy testosterone production.
Finished products that include KSM-66 at a 300-mg dose can use the following claims:
An NPN license indicates that Health Canada has reviewed a product-including clinical study evidence-and deemed it safe, effective, and of high quality.
Because KSM-66’s extract comes from the root of the ashwagandha plant (Withania somnifera), it meets specifications of Health Canada’s own ashwagandha monograph, as well as specifications of the U.S. Pharmacopeia and the British Pharmacopeia.
“Because KSM-66 uses only the root and no other part of the ashwagandha plant, and because Health Canada’s own ashwagandha monograph similarly specifies only the root, these [newly approved health] claims are over and above what is available to formulators who reference the generic Health Canada ashwagandha monograph,” said KSM-66’s supplier Ixoreal Biomed (Hyderabad, India), in a press release.
Also, because the root is what’s most often referenced in clinical ashwagandha studies, “this probably puts KSM-66 on more familiar ground in the minds of governmental regulators across the world,” adds Kartikeya Baldwa, director, Ixoreal.
KSM-66’s NPN is #80047973.
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine jennifer.grebow@ubm.com
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.